Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Valproate semisodium is mainly metabolised by glucuronidation with CYP-mediated metabolism being relatively minor; these pathways are not expected to be affected by elbasvir/grazoprevir.